|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brown M, Tsodikov A, Bauer KR, Parise CA
and Caggiano V: The role of human epidermal growth factor receptor
2 in the survival of women with estrogen and progesterone
receptor-negative, invasive breast cancer: The California Cancer
Registry, 1999-2004. Cancer. 112:737–747. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Duffy MJ, McGowan PM and Crown J: Targeted
therapy for triple-negative breast cancer: Where are we? Int J
Cancer. 131:2471–2477. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gradishar WJ, Anderson BO, Abraham J, Aft
R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD,
et al: Breast cancer, version 3.2020, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 18:452–478. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kobayashi A, Ito E, Toki T, Kogame K,
Takahashi S, Igarashi K, Hayashi N and Yamamoto M: Molecular
cloning and functional characterization of a new Cap'n’ collar
family transcription factor Nrf3. J Biol Chem. 274:6443–6452. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Motohashi H, O'Connor T, Katsuoka F, Engel
JD and Yamamoto M: Integration and diversity of the regulatory
network composed of Maf and CNC families of transcription factors.
Gene. 294:1–12. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sekine H and Motohashi H: Roles of CNC
transcription factors NRF1 and NRF2 in cancer. Cancers (Basel).
13:5412021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yuan J, Zhang S and Zhang Y: Nrf1 is paved
as a new strategic avenue to prevent and treat cancer,
neurodegenerative and other diseases. Toxicol Appl Pharmacol.
360:273–283. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rojo de la Vega M, Chapman E and Zhang DD:
NRF2 and the hallmarks of cancer. Cancer Cell. 34:21–43. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Derjuga A, Gourley TS, Holm TM, Heng HH,
Shivdasani RA, Ahmed R, Andrews NC and Blank V: Complexity of CNC
transcription factors as revealed by gene targeting of the Nrf3
locus. Mol Cell Biol. 24:3286–3294. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He F, Ru X and Wen T: NRF2, a
transcription factor for stress response and beyond. Int J Mol Sci.
21:47772020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Radhakrishnan SK, Lee CS, Young P, Beskow
A, Chan JY and Deshaies RJ: Transcription factor Nrf1 mediates the
proteasome recovery pathway after proteasome inhibition in
mammalian cells. Mol Cell. 38:17–28. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kobayashi A: Roles of NRF3 in the
hallmarks of cancer: Proteasomal inactivation of tumor suppressors.
Cancers (Basel). 12:26812020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Braun S, Hanselmann C, Gassmann MG, Auf
Dem Keller U, Born-Berclaz C, Chan K, Kan YW and Werner S: Nrf2
transcription factor, a novel target of keratinocyte growth factor
action which regulates gene expression and inflammation in the
healing skin wound. Mol Cell Biol. 22:5492–5505. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pepe AE, Xiao Q, Zampetaki A, Zhang Z,
Kobayashi A, Hu Y and Xu Q: Crucial role of nrf3 in smooth muscle
cell differentiation from stem cells. Circ Res. 106:870–979. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bury M, Le Calvé B, Lessard F, Dal Maso T,
Saliba J, Michiels C, Ferbeyre G and Blank V: NFE2L3 controls colon
cancer cell growth through regulation of DUX4, a CDK1 inhibitor.
Cell Rep. 29:1469–1481.e9. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qian J, Huang C, Zhu Z, He Y, Wang Y, Feng
N, He S, Li X, Zhou L, Zhang C and Gong Y: NFE2L3 promotes tumor
progression and predicts a poor prognosis of bladder cancer.
Carcinogenesis. 43:457–468. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Waku T, Nakamura N, Koji M, Watanabe H,
Katoh H, Tatsumi C, Tamura N, Hatanaka A, Hirose S, Katayama H, et
al: NRF3-POMP-20S proteasome assembly axis promotes cancer
development via ubiquitin-independent proteolysis of p53 and
retinoblastoma protein. Mol Cell Biol. 40:e00597–19. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yin L, Duan JJ, Bian XW and Yu SC:
Triple-negative breast cancer molecular subtyping and treatment
progress. Breast Cancer Res. 22:612020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Katso R, Okkenhaug K, Ahmadi K, White S,
Timms J and Waterfield MD: Cellular function of phosphoinositide
3-kinases: Iimplications for development, homeostasis, and cancer.
Annu Rev Cell Dev Biol. 17:615–675. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gjelaj E and Hamel PA: Distinct
epithelial-to-mesenchymal transitions induced by PIK3CA (H1047R)
and PIK3CB. J Cell Sci. 134:jcs2482942021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Grille SJ, Bellacosa A, Upson J,
Klein-Szanto AJ, van Roy F, Lee-Kwon W, Donowitz M, Tsichlis PN and
Larue L: The protein kinase Akt induces epithelial mesenchymal
transition and promotes enhanced motility and invasiveness of
squamous cell carcinoma lines. Cancer Res. 63:2172–2178.
2003.PubMed/NCBI
|
|
25
|
Cai BQ, Chen WW, Zhao JA, Hou W and Tang
JC: Nrf3 Promotes 5-FU resistance in colorectal cancer cells via
the NF-κB/BCL-2 signaling pathway in vitro and in vivo. J Oncol.
2021:93555552021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bolger AM, Lohse M and Usadel B:
Trimmomatic: A flexible trimmer for Illumina sequence data.
Bioinformatics. 30:2114–2120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim D, Langmead B and Salzberg SL: HISAT:
A fast spliced aligner with low memory requirements. Nat Methods.
12:357–360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Trapnell C, William BA, Pertea G,
AMortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ and
Pachter L: Transcript assembly and quantification by RNA-Seq
reveals unannotated transcripts and isoform switching during cell
differentiation. Nat Biotechnol. 28:511–515. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Anders S, Pyl PT and Huber W: HTSeq-a
Python framework to work with high-throughput sequencing data.
Bioinformatics. 31:166–169. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Anders S and Huber W: Differential
expression of RNA-Seq data at the gene level-the DESeq package.
EMBL; 2013
|
|
31
|
Hänzelmann S, Castelo R and Guinney J:
GSVA: Gene set variation analysis for microarray and RNA-seq data.
BMC Bioinformatics. 14:72013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chowdhury A, Katoh H, Hatanaka A, Iwanari
H, Nakamura N, Hamakubo T, Natsume T, Waku T and Kobayashi A:
Multiple regulatory mechanisms of the biological function of NRF3
(NFE2L3) control cancer cell proliferation. Sci Rep. 7:124942017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Immonen A, Haapasaari KM, Skarp S,
Karihtala P and Teppo HR: NRF3 decreases during melanoma
carcinogenesis and is an independent prognostic marker in melanoma.
Oxid Med Cell Longev. 2022:22402232022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Waku T, Katayama H, Hiraoka M, Hatanaka A,
Nakamura N, Tanaka Y, Tamura N, Watanabe A and Kobayashi A: NFE2L1
and NFE2L3 complementarily maintain basal proteasome activity in
cancer cells through CPEB3-mediated translational repression. Mol
Cell Biol. 40:e00010–20. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chevillard G, Paquet M and Blank V: Nfe2l3
(Nrf3) deficiency predisposes mice to T-cell lymphoblastic
lymphoma. Blood. 117:2005–2008. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yu MM, Feng YH, Zheng L, Zhang J and Luo
GH: Short hairpin RNA-mediated knockdown of nuclear factor
erythroid 2-like 3 exhibits tumor-suppressing effects in
hepatocellular carcinoma cells. World J Gastroenterol.
25:1210–1223. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sun J, Zheng Z, Chen Q, Pan Y, Lu H, Zhang
H, Yu Y and Dai Y: NRF3 suppresses breast cancer cell metastasis
and cell proliferation and is a favorable predictor of survival in
breast cancer. Onco Targets Ther. 12:3019–3030. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xie G, Ji A, Yuan Q, Jin Z, Yuan Y, Ren C,
Guo Z, Yao Q, Yang K, Lin X and Chen L: Tumour-initiating capacity
is independent of epithelial-mesenchymal transition status in
breast cancer cell lines. Br J Cancer. 110:2514–2523. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tang Y and Wang S, Li Y, Yuan C, Zhang J,
Xu Z, Hu Y, Shi H and Wang S: Simultaneous glutamine metabolism and
PD-L1 inhibition to enhance suppression of triple-negative breast
cancer. J Nanobiotechnology. 20:2162022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Miricescu D, Totan A, Stanescu-Spinu II,
Badoiu SC, Stefani C and Greabu M: PI3K/AKT/mTOR signaling pathway
in breast cancer: From molecular landscape to clinical aspects. Int
J Mol Sci. 22:1732020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Costa RLB, Han HS and Gradishar WJ:
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast
cancer: A review. Breast Cancer Res Treat. 169:397–406. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Aiello NM and Kang Y: Context-dependent
EMT programs in cancer metastasis. J Exp Med. 216:1016–1026. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chaffer CL, San Juan BP, Lim E and
Weinberg RA: EMT, cell plasticity and metastasis. Cancer Metastasis
Rev. 35:645–654. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bobal P, Lastovickova M and Bobalova J:
The Role of ATRA, natural ligand of retinoic acid receptors, on
EMT-related proteins in breast cancer: Minireview. Int J Mol Sci.
22:133452021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ren YG, Wang YJ, Hao S, Yang YH, Xiong WD
and Qiu L: NFE2L3 promotes malignant behavior and EMT of human
hepatocellular carcinoma (HepG2) cells via Wnt/β-catenin pathway. J
Cancer. 11:6939–6949. 2020. View Article : Google Scholar : PubMed/NCBI
|
